Regenerative tissue specialist Tissue Regenix (LON:TRX) has agreed a major expansion of its development partnership with the NHS’s blood and transplant unit, NHSBT.
The company, which has pioneered a technology that can swap worn out or damaged body parts with replacements taken from a human donor or animal, already has a chronic wound trial under way with NHSBT under its original deal.
That trial hit the headlines recently when a 92 -year old grandmother was successfully treated for leg ulcers at University Hospital South Manchester using Tissue Regenix’s dCell process and skin taken from dead donors.
Tissue’s original deal gave NHSBT have the right to carry out pre-clinical and clinical evaluations.
The extended agreement means Tissue can now can fast-track clinical evaluation of new applications of dCell with NHSBT.
It is currently developing replacement cartilages, ligaments, heart valves, and skin and vascular patches using dCell technology
The company said NHSBT will also become a global Centre of Excellence for dCell.
Antony Odell, Tissue Regenix’s managing director, said: "NHSBT has unparalleled relationships with the NHS clinical community and world-class development facilities and these will enable us to jointly address a range of significant clinical needs in a cost and time efficient manner".
Helen Gillan, NHSBT’s head of Tissue Services, added "We welcome the expansion of our partnership with Tissue Regenix.
“Currently, we have a clinical trial underway using decellularised human donor skin grafts in the treatment of chronic, non-healing wounds. Although it is a relatively new trial, it is already showing great promise," she added.